Media stories about Charles River Laboratories (NYSE:CRL) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Charles River Laboratories earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.7908071580288 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Charles River Laboratories (CRL) Research Coverage Started at Mitsubishi UFJ Financial Group (americanbankingnews.com)
- Charles River Laboratories International Breaks Below 200-Day Moving Average – Notable for CRL (nasdaq.com)
- National Research (NRCIB) & Charles River Laboratories (CRL) Head-To-Head Contrast (americanbankingnews.com)
- Charles River Laboratories (CRL) Rating Reiterated by Barclays (americanbankingnews.com)
- $481.32 Million in Sales Expected for Charles River Laboratories (CRL) This Quarter (americanbankingnews.com)
CRL has been the topic of several research analyst reports. Credit Suisse Group restated a “hold” rating and set a $108.00 target price on shares of Charles River Laboratories in a research note on Thursday, February 15th. TheStreet cut shares of Charles River Laboratories from an “a-” rating to a “c+” rating in a research note on Tuesday, February 13th. Barclays restated a “hold” rating and set a $110.00 target price on shares of Charles River Laboratories in a research note on Friday, February 16th. JPMorgan Chase upped their target price on shares of Charles River Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. Finally, Evercore ISI initiated coverage on shares of Charles River Laboratories in a research note on Thursday, January 18th. They set an “in-line” rating and a $117.00 target price on the stock. Nine investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $116.71.
Charles River Laboratories (NYSE:CRL) last issued its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.26 by $0.14. Charles River Laboratories had a net margin of 6.64% and a return on equity of 26.14%. The firm had revenue of $478.50 million for the quarter, compared to analysts’ expectations of $475.02 million. During the same quarter in the prior year, the business earned $1.21 EPS. The business’s quarterly revenue was up 2.5% on a year-over-year basis. analysts expect that Charles River Laboratories will post 5.77 EPS for the current fiscal year.
In other news, CEO James C. Foster sold 4,800 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $106.69, for a total value of $512,112.00. Following the transaction, the chief executive officer now owns 306,914 shares in the company, valued at approximately $32,744,654.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William D. Barbo sold 2,320 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $108.08, for a total transaction of $250,745.60. Following the completion of the transaction, the insider now owns 21,276 shares in the company, valued at approximately $2,299,510.08. The disclosure for this sale can be found here. Insiders sold a total of 62,658 shares of company stock worth $6,875,393 in the last quarter. Company insiders own 2.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Charles River Laboratories (CRL) Earns Coverage Optimism Rating of 0.12” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://stocknewstimes.com/2018/04/23/charles-river-laboratories-crl-earns-coverage-optimism-rating-of-0-12.html.
About Charles River Laboratories
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.